Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An All-Oral Combination Study of AB-506 and AB-452

Trial Profile

An All-Oral Combination Study of AB-506 and AB-452

Phase of Trial: Phase I

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs AB-452 (Primary) ; AB-506 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jul 2018 New trial record
    • 10 Jul 2018 According to an Arbutus Biopharma media release, the company expects to initiate this trial in 2H 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top